cyclotherapeutics.com (CYTH) Quarterly EPS earnings growth

Symbol and logo of brand Cyclo Therapeutics, Inc (CYTH)

The quarterly EPS growth rate reflects the revenue dynamics of Cyclo Therapeutics, where the value -4.30 describes the current level. Cyclo Therapeutics generates earnings by creating innovations for Alzheimer's patients through government payments. A virtual development model and outsourced synthesis ensure supply stability. Anticipation of the Trappsol Cyclo Phase 3 trial results, despite factored-in losses, serves as the primary driver.

CYTH: Cyclo Therapeutics, Inc. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 04/05/2025

Cyclo Therapeutics (CYTH) - metric breakdowns and financial figures

Initial company analysis:Cyclo Therapeutics
Flagship merchandise of Cyclo Therapeutics, Inc

Cyclo Therapeutics (CYTH) operates in the growing segment of rare genetic pathology therapies, where the expansion of clinics directly impacts the commercialization of molecules. Equity value dynamics, analyzed through quarterly earnings per share (EPS) growth, allow for an assessment of cash flow predictability, while the rate of quarterly EPS growth serves as an indicator of asset reliability and the risk of capital stagnation should the sector slow down.

Who Cyclo Therapeutics competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Therapeutics)|ARCT: Quarterly EPS earnings growth|Eton Pharmaceuticals Inc (ETON) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Kamada Corp|FULC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Abeona Therapeutics, Inc. (ABEO)|Year-over-year net earnings per share growth for the last 12 months Mereo BioPharma Group plc MREO|Year-over-year earnings per share growth for the last twelve months Protalix BioTherapeutics PLX|Quarterly EPS earnings growth Pliant Therapeutics PLRX|appliedtherapeutics.com - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months RNTX (Rein Therapeutics, Inc.)|GELS: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aytu BioPharma, Inc. (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months SRXH (SRx Health Solutions)|Year-over-year net earnings per share growth for the last 12 months PLRZ (Polyrizon Ltd)|AEZS - Earnings per share growth in annualized terms for the last twelve months|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth